Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short-course blinatumomab plus short-cycle chemotherapy vs standard chemotherapy in newly diagnosed Ph-negative B-ALL
ChiCTR2600127006Phase 2Not yet recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2026
- Modality
- T-cell Engagers → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, scFv Fragments → Antibody Fragments → Engineered Antibody Formats → Antibody-Based Therapeutics, Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial of blinatumomab in acute lymphoblastic leukemia (ALL) (2 arms), sponsored by Henan Cancer Hospital. Primary endpoint: MRD negative conversion rate at day 28 of induction. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
acute lymphoblastic leukemia (ALL)
Beyond the preview
Go deeper on ChiCTR2600127006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600127006.